Wells Fargo’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-287
| Closed | -$23 | – | 7914 |
|
|
2022
Q4 | $23 | Sell |
287
-475
| -62% | -$60 | ﹤0.01% | 7252 |
|
|
2022
Q3 | $0 | Buy |
762
+491
| +181% | +$103 | ﹤0.01% | 7808 |
|
|
2022
Q2 | $0 | Buy |
271
+98
| +57% | +$25 | ﹤0.01% | 7906 |
|
|
2022
Q1 | $0 | Buy |
173
+25
| +17% | +$27 | ﹤0.01% | 8216 |
|
|
2021
Q4 | $0 | Sell |
148
-8
| -5% | -$24 | ﹤0.01% | 8143 |
|
|
2021
Q3 | $0 | Buy |
156
+105
| +206% | +$398 | ﹤0.01% | 7802 |
|
|
2021
Q2 | $0 | Hold |
51
| – | – | ﹤0.01% | 7734 |
|
|
2021
Q1 | $0 | Buy |
51
+17
| +50% | +$93 | ﹤0.01% | 7637 |
|
|
2020
Q4 | $0 | Hold |
34
| – | – | ﹤0.01% | 7281 |
|
|
2020
Q3 | $0 | Sell |
34
-423
| -93% | -$974 | ﹤0.01% | 7169 |
|
|
2020
Q2 | $1K | Buy |
457
+425
| +1,328% | +$768 | ﹤0.01% | 6216 |
|
|
2020
Q1 | $0 | Buy |
+32
| New | +$65 | ﹤0.01% | 7060 |
|
|
2019
Q4 | – | Sell |
-121
| Closed | – | – | 6877 |
|
|
2019
Q3 | $0 | Hold |
121
| – | – | ﹤0.01% | 6859 |
|
|
2019
Q2 | $0 | Buy |
121
+75
| +163% | +$116 | ﹤0.01% | 6723 |
|
|
2019
Q1 | $0 | Sell |
46
-2
| -4% | -$3 | ﹤0.01% | 6590 |
|
|
2018
Q4 | $0 | Sell |
48
-152
| -76% | -$262 | ﹤0.01% | 6698 |
|
|
2018
Q3 | $0 | Hold |
200
| – | – | ﹤0.01% | 6655 |
|
|
2018
Q2 | $0 | Buy |
200
+50
| +33% | +$139 | ﹤0.01% | 6668 |
|
|
2018
Q1 | $0 | Hold |
150
| – | – | ﹤0.01% | 6647 |
|
|
2017
Q4 | $0 | Sell |
150
-300
| -67% | -$912 | ﹤0.01% | 6603 |
|
|
2017
Q3 | $1K | Buy |
+450
| New | +$1.27K | ﹤0.01% | 6257 |
|
|
2016
Q2 | – | Sell |
-51
| Closed | – | – | 6415 |
|
|
2016
Q1 | $0 | Sell |
51
-500
| -91% | -$1.68K | ﹤0.01% | 6515 |
|
|
2015
Q4 | $2K | Sell |
551
-105
| -16% | -$423 | ﹤0.01% | 6038 |
|
|
2015
Q3 | $3K | Buy |
656
+425
| +184% | +$1.73K | ﹤0.01% | 5945 |
|
|
2015
Q2 | $1K | Sell |
231
-294
| -56% | -$885 | ﹤0.01% | 6273 |
|
|
2015
Q1 | $2K | Buy |
525
+350
| +200% | +$1.44K | ﹤0.01% | 5991 |
|
|
2014
Q4 | $1K | Buy |
175
+125
| +250% | +$978 | ﹤0.01% | 6120 |
|
|
2014
Q3 | $0 | Sell |
50
-100
| -67% | -$917 | ﹤0.01% | 6406 |
|
|
2014
Q2 | $1K | Hold |
150
| – | – | ﹤0.01% | 6038 |
|
|
2014
Q1 | $2K | Hold |
150
| – | – | ﹤0.01% | 5709 |
|
|
2013
Q4 | $3K | Sell |
150
-644
| -81% | -$17.5K | ﹤0.01% | 5497 |
|
|
2013
Q3 | $24K | Buy |
794
+525
| +195% | +$17.4K | ﹤0.01% | 4909 |
|
|
2013
Q2 | $9K | Buy |
+269
| New | +$9.26K | ﹤0.01% | 5097 |
|
Other funds holding STAB
Wells Fargo's STAB Position: Q1 2023 in Review
Wells Fargo sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2023, closing a stake of 287 shares — an estimated $23 sold.
Wells Fargo first reported a position in STAB in Q2 2013 and held it in 33 quarters. The position peaked at $24K in Q3 2013. 4 funds tracked by Wall St. Rank hold STAB as of Q1 2023.
- Wells Fargo reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- Wells Fargo sold 287 Statera Biopharma, Inc. Common Stock shares in Q1 2023, an estimated $23.
- Wells Fargo first reported a position in Statera Biopharma, Inc. Common Stock in Q2 2013 and held it in 33 quarters.
- Wells Fargo's Statera Biopharma, Inc. Common Stock position peaked at $24K in Q3 2013.
- 4 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2023.
Based on Wells Fargo's 13F filing for Q1 2023, filed 12 May 2023.